To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

September 19, 2017

Today's Rundown

  1. Ex-Glaxo CEO Witty joins Hatteras as venture partner

  2. Acceleron takes back drug rights from Celgene to start pulmonary push

  3. Atlas neurological upstart Disarm gains $30M, AbbVie backing

  4. [Sponsored] The Path to Digital Transformation in Life Sciences: How to get started with IoT

  5. Aerie raids Alcon again, returning this time with an R&D VP

  6. Johnson & Johnson, BARDA join forces to prep for pandemic flu, inking deal for vaccine and drug R&D

  7. Catalent doubles down on biologics with $950M deal for Cook Pharmica

Featured Story

Ex-Glaxo CEO Witty joins Hatteras as venture partner

Sir Andrew Witty has joined Hatteras Venture Partners. The former GlaxoSmithKline CEO is taking up a venture partner position at the VC shop, setting him up to offer advice on the positioning of its portfolio companies.

Top Stories

Acceleron takes back drug rights from Celgene to start pulmonary push

Acceleron's long-running collaboration with Celgene on sotatercept has taken another turn today, with an amendment of their agreement to give Acceleron the right to develop the drug for pulmonary diseases.

Atlas neurological upstart Disarm gains $30M, AbbVie backing

Disarm Therapeutics has seen a strong $30 million series A round as it looks for a breakthrough approach in axonal degeneration.

[Sponsored] The Path to Digital Transformation in Life Sciences: How to get started with IoT

For pharma and biotech, in which data is the most valuable asset, industry analysts agree that digital transformation presents an opportunity to realize unprecedented productivity gains and competitive advantage.

Aerie raids Alcon again, returning this time with an R&D VP

Aerie Pharmaceuticals has yet again looked to Novartis’ struggling eye care unit for a new hire. Eric Carlson, Ph.D., has become the latest in a string of former Alcon employees to land at the smaller eye disease specialist.

Johnson & Johnson, BARDA join forces to prep for pandemic flu, inking deal for vaccine and drug R&D

After deadly outbreaks that caught scientists and providers off guard, vaccine experts may be happy to see Johnson & Johnson and a U.S. development agency collaborate on pandemic flu. In a novel agreement, they've paired up to focus on a vaccine program and potential flu drugs from J&J.

Catalent doubles down on biologics with $950M deal for Cook Pharmica

Catalent signaled a year ago that it was looking for the right M&A target to bulk up like some of its competitors have. Now it says it has found one, having agreed to pay $950 million to buy Cook Pharmica and its extensive biologics manufacturing operation in Bloomington, Indiana.

Resources

[Webinar] Five ways to make your patient support program a success

Join this webinar to learn how to design, deliver, and measure a successful patient support program. Presented by Nareda Mills, Ashfield's SVP of Patient Services in the US, you’ll discover how to improve adherence and improve patient outcomes using 5 key methods.

[Whitepaper] The Impact of Contraceptive Requirements on Pediatric Clinical Trials

Children participating in pediatric clinical trials are included in the contraceptive requirements applied to women of child-bearing potential, creating significant challenges for sponsors, parents, investigators and study staff.

[Webinar] Within-Subject Clinical Trials: Intro to New Methods & Stat. Models

In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods.

Events

.